Evaluation and ethical review of a tool to explore patient preferences for information and involvement in decision making

AIM

To improve clinical and ethical understanding of patient preferences for information and involvement in decision making.

OBJECTIVES

To develop and evaluate a clinical tool to elicit these preferences and to consider the ethical issues raised.

DESIGN

A before and after study.

SETTING

Three UK hospices.

PARTICIPANTS

Patients with advanced life-threatening illnesses and their doctors.

INTERVENTION

Questionnaire on information and decision-making preferences.

MAIN OUTCOME MEASURES

Patient-based outcome measures were satisfaction with the amount of information given, with the way information was given, with family or carer information, and confidence about future decision making. Doctor-based outcome measures were confidence in matching information to patient preference, matching family or carer communication to patient preference, knowing patient preferences and matching future decision making with patient preference.

RESULTS

Of 336 admissions, 101 patients (mean age 67.3 years, 47.5% men) completed the study (control, n = 40; intervention, n = 61). Patient satisfaction with the way information was given (chi2 = 6.38, df = 2, p = 0.041) and family communication (chi2 = 14.65, df = 2, p < 0.001) improved after introduction of the tool. Doctor confidence improved across all outcome measures (all p values < 0.001).

CONCLUSIONS

Patient satisfaction and doctor confidence were improved by administering the questionnaire, but complex ethical issues were raised by implementing and applying this research. The balance of ethical considerations were changed by advanced life-threatening illness, because there is increased risk of harm through delivery of information discordant with the patient's own preferences. The importance of truly understanding patient preferences towards the end of life is highlighted by this study.

Pruritus in cancer patients

Pruritus is an uncommon symptom in cancer patients but can often be difficult to treat. The pathogenesis is complex and is not fully understood although there is evidence of involvement of a number of mediators from which treatment options are developing. In cancer patients pruritus may be directly related to the cancer, indirectly related (e.g. cholestasis) or associated with treatment. It is not always possible to treat the underlying cause of the pruritus in these patients, or desirable to stop treatments that may contribute and in these cases we must address the pruritus itself. The treatment of pruritus is a developing area, and helpful research is slowly emerging. The evidence base is not extensive but some high quality studies exist. This short paper briefly discusses the pathogenesis, causes, effects and treatment options for pruritus in cancer patients.

Opioid use in last week of life and implications for end-of-life decision-making

This study was prompted by public and professional concern that the use of opioids for symptom control might shorten life. We retrospectively analysed the pattern of opioid use in the last week of life in 238 consecutive patients who died in a palliative care unit. Median doses of opioid were low (26.4 mg) in the last 24 h of life and patients who received opioid increases at the end of life did not show shorter survival than those who received no increases. The doctrine of double effect therefore need not be invoked to provide symptom control at the end of life.

Resuscitation in palliative care

‘They were going to let me die’, said Jill Baker, a 67-year-old woman who found herself ‘not for resuscitation’ during a hospital stay in 1999 (The Guardian, 2000). This demonstrates the misconceptions held by both public and professionals regarding cardiopulmonary resuscitation (CPR).